UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

Form 8-K

Current Report

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 27, 2019

CYTORI THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

	Delaware	001-34375	33-0827593
	(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification Number)
		athon Blvd., Suite 200, Austin of principal executive offices, v	
	(z ida ess	or principal executive offices, v	viui zip code)
		(858) 458-0900	
	(Registra	ınt's telephone number, includir	g area code)
		N/A	
	(Former nam	e or former address, if changed	since last report)
	he appropriate box below if the Form 8-K filing is in ons (see General Instruction A.2. below):	ntended to simultaneously satisfy t	ne filing obligation of the registrant under any of the following
	Written communications pursuant to Rule 425 und	ler the Securities Act (17 CFR 230	.425)
	□ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)		
	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))		
	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))		
	by check mark whether the registrant is an emergin or Rule 12b-2 of the Securities Exchange Act of 19		ule 405 of the Securities Act of 1933 (§ 230.405 of this
Emergii	ng growth company \square		
	nerging growth company, indicate by check mark if t financial accounting standards provided pursuant to	•	the extended transition period for complying with any new or . \Box
	Securities	registered pursuant to Section 12	2(b) of the Act:
	Title of each class	Trading Symbol(s)	Name of each exchange on which registered

CYTX

Nasdaq Capital Market

Common Stock, par value \$0.001

Item 8.01. Other Events.

On June 27, 2019, Cytori Therapeutics, Inc. (the "Company") reconvened its 2019 Annual Meeting of Stockholders (the "Annual Meeting"). The Company then adjourned the Annual Meeting before any of the proposals set forth in the Company's Definitive Proxy Statement on Schedule 14A, filed with the Securities and Exchange Commission on April 19, 2019 (the "Proxy Statement"), were voted upon. In announcing the adjournment of the Annual Meeting, the chairman of the meeting announced that the Annual Meeting will reconvene on July 11, 2019 at 9:00 a.m., Central Time, at the Company's offices at 4200 Marathon Blvd., Suite 200, Austin Texas 78756. The Company does not expect any items of business at the reconvened Annual Meeting other than those set forth in the Proxy Statement.

A copy of the press release announcing the adjournment of the Annual Meeting is attached hereto as Exhibit 99.1.

Item 9.01 Financial Statements and Exhibits.

The following exhibits are furnished as part of this Current Report on Form 8-K:

(d) Exhibits.

99.1 <u>Press Release, dated June 27, 2019.</u>

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: June 27, 2019

CYTORI THERAPEUTICS, INC.

By: /s/ Gary Titus

Gary Titus

Chief Financial Officer

Cytori Announces New Annual Stockholders Meeting Date for July 11

Annual Meeting Adjourned to Provide Additional Time to Obtain Approval of Key Business

SAN DIEGO, CA — (GLOBE NEWSWIRE) Cytori Therapeutics, Inc. (Nasdaq: CYTX) today announced that it reconvened its annual meeting of stockholders on Thursday, June 27, 2019 and adjourned the meeting until Thursday, July 11, 2019, at 9:00 a.m., Central Time. The annual meeting was adjourned to allow the Company's stockholders an additional opportunity to evaluate Proposal 4, relating to the approval of a reverse stock split of the Company's common stock. Although more than 69% of the votes cast were in favor of the reverse stock split (Proposal 4), this constitutes approximately 48% of the Company's outstanding shares of common stock and approval requires the affirmative vote of a majority of the outstanding shares of common stock.

The annual meeting was adjourned until 9:00 a.m., Central Time, on July 11, 2019 at 4200 Marathon Blvd., Suite 200, Austin Texas 78756, the Company's offices in Austin, Texas. The record date for the annual meeting remains March 29, 2019. Stockholders that have yet to vote are requested to do so prior to the new July 11 meeting date and are encouraged to vote in favor of the reverse stock split as outlined in the Company's proxy materials.

Stockholders who have previously sent in proxy cards or given instructions to brokers do not need to re-cast their votes unless they want to change their vote. Proxies previously submitted in respect of the meeting will be voted at the adjourned meeting unless properly revoked.

If stockholders have questions, need help voting shares, or want to change a vote in favor of Proposal 4, please call The Proxy Advisory Group, LLC, which is assisting the Company in this matter at 1-888-557-7699 or 1-888-55PROXY.

About Cytori Therapeutics, Inc.

Cytori is developing, manufacturing, and commercializing nanoparticle-delivered oncology drugs. Cytori is focused on the liposomal encapsulation of anti-neoplastic chemotherapy agents or other drugs which may enable the effective delivery of the agents to target sites while reducing systemic toxicity and improving pharmacokinetics. Cytori's pipeline consists of ATI-0918 pegylated liposomal doxorubicin hydrochloride for breast cancer, ovarian cancer, multiple myeloma, and Kaposi's sarcoma, a complex/hybrid generic drug, and ATI-1123 patented albumin-stabilized pegylated liposomal docetaxel for multiple solid tumors. For more information, please visit www.cytori.com.

Cytori Therapeutics, Inc.

Gary Titus, +1 (858) 458.0900 ir@cytori.com